Skip to content

Study · Not a test of the peptide alone · 2026

2 results

Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence.

Ning N, Wang C, Gao T, Ma J, Ding M, Zhang F, Liu Q, Zhang W, Gong L

Molecular carcinogenesis2 Jul 2026Cited by 1 (Europe PMC)

PMID42391447 (opens in a new tab)PMCIDPMC13466165 (opens in a new tab)DOI10.1002/mc.70134 (opens in a new tab)PepBankPUB-42391447
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, FOXO4-DRI was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking FOXO4-DRI.

  1. 01LabNot a test of FOXO4-DRI aloneIn vitro (cells)Efficacy outcome

    In glioblastoma cell experiments, FOXO4‑DRI combined with temozolomide enhanced the therapeutic efficacy of temozolomide.

    In plain wordsIn glioblastoma cell tests, adding FOXO4‑DRI to temozolomide made the drug work better.

    Peptide
    FOXO4-DRI
    Outcome
    IncreaseEfficacy of temozolomide combined with FOXO4-DRI
    Study

    n: not reported in source

    Glioblastoma cell experiments
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Conversely, Mito-TEMPO, a mtROS scavenger, and FOXO4-DRI, a senolytic agent, both enhanced the therapeutic efficacy of TMZ by eliminating these senescent cells via apoptosis.
    1 context sentence
    Summary · context
    Here, we aimed to investigate the role of AGK in GBM progression and TMZ resistance, assessed whether CSEN mediates these effects, and investigated the therapeutic potential of senolytic agents.

    In this study, FOXO4-DRI was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking FOXO4-DRI.

  2. 02LabNot a test of FOXO4-DRI aloneIn vitro (cells)Mechanism

    In glioblastoma cell experiments, FOXO4‑DRI combined with temozolomide eliminated senescent cells via apoptosis.

    In plain wordsIn glioblastoma cell tests, FOXO4‑DRI together with temozolomide cleared aged cells by triggering cell death.

    Peptide
    FOXO4-DRI
    Outcome
    IncreaseApoptotic elimination of senescent cells with temozolomide plus FOXO4-DRI
    Study

    n: not reported in source

    Glioblastoma cell experiments
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Conversely, Mito-TEMPO, a mtROS scavenger, and FOXO4-DRI, a senolytic agent, both enhanced the therapeutic efficacy of TMZ by eliminating these senescent cells via apoptosis.
    1 context sentence
    Summary · context
    Here, we aimed to investigate the role of AGK in GBM progression and TMZ resistance, assessed whether CSEN mediates these effects, and investigated the therapeutic potential of senolytic agents.

    In this study, FOXO4-DRI was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking FOXO4-DRI.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.